InvestorsHub Logo
Followers 3
Posts 109
Boards Moderated 0
Alias Born 01/12/2024

Re: BonnieMac post# 197271

Tuesday, 04/23/2024 11:45:40 PM

Tuesday, April 23, 2024 11:45:40 PM

Post# of 198997
Agreed. The company has not been transparent in the least. I have the following specific questions:
1) Did the SAGA deal go through? It doesn't appear to have gone through. Biogenysis and Virogentics appear to be part of ENZC. The Biogenysis website is down -- perhaps for the same reason that the ENZC website was down. If ENZC comments when the website is restored, I'll be confident that both Biogenysis and Virogentics are definitely still in the ENZC family.
2) Is the SAGA deal still in the works?
3) ENZC's exec team is clearly taking the company in a new direction. The verbiage in today's AccessWire article layered on more anxiety for SH's (at least me). To my knowledge, only Virogentics has ANY experience in "Sales, Marketing and Distribution". Let's be honest here -- it isn't much experience. I'm thinking WTF?
4) How does Dr. Chandra fit into the company's future? Is he still CEO of Biogenysis and a ENZC Board member?
5) I've read many times that the patents (intellectual property) are held in the "Zhabilov Trust" and that ENZC/Biogenysis is the exclusive licensee for the patents. ENZC's future value has been all about the future value of the intellectual property. Now the exec team is changing the strategy/model to "sales, marketing and distribution". What are they selling, marketing and distributing? Surely not "IPF Immune Support". Is the new strategy wrapped around AI and human monoclonal antibodies? If so, they're basically selling/marketing/distributing intellectual property.

Well, I just don't know. Does anyone?